Subscribe
bill-oxford
Bill Oxford / IStockphoto.com
29 October 2018Americas

J&J reveals plans to appeal cancer drug court ruling

Johnson & Johnson (J&J) has revealed its intention to appeal against a district court’s invalidation of a patent covering its prostate cancer drug Zytiga (abiraterone acetate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

More on this story

Big Pharma
Federal Circuit rules against J&J in Zytiga dispute
16 May 2019   The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
Big Pharma
Johnson & Johnson braces for Q3 sales dip as generics bite
18 July 2019   Johnson & Johnson has warned that strong competition from generic drugs could impact the company’s figures for the rest of the year.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers